Abbott Laboratories Current Ratio 2010-2024 | ABT
Current and historical current ratio for Abbott Laboratories (ABT) from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Abbott Laboratories current ratio for the three months ending September 30, 2024 was 1.60.
| Abbott Laboratories Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2024-09-30 | $23.80B | $14.90B | 1.60 |
| 2024-06-30 | $23.12B | $13.76B | 1.68 |
| 2024-03-31 | $22.38B | $14.02B | 1.60 |
| 2023-12-31 | $22.67B | $13.84B | 1.64 |
| 2023-09-30 | $22.66B | $13.04B | 1.74 |
| 2023-06-30 | $23.51B | $14.35B | 1.64 |
| 2023-03-31 | $24.38B | $14.53B | 1.68 |
| 2022-12-31 | $25.22B | $15.49B | 1.63 |
| 2022-09-30 | $24.85B | $13.37B | 1.86 |
| 2022-06-30 | $24.96B | $12.39B | 2.01 |
| 2022-03-31 | $23.43B | $12.65B | 1.85 |
| 2021-12-31 | $24.24B | $13.11B | 1.85 |
| 2021-09-30 | $23.49B | $12.87B | 1.83 |
| 2021-06-30 | $22.63B | $12.61B | 1.79 |
| 2021-03-31 | $21.82B | $12.46B | 1.75 |
| 2020-12-31 | $20.44B | $11.91B | 1.72 |
| 2020-09-30 | $17.39B | $10.26B | 1.70 |
| 2020-06-30 | $17.22B | $10.96B | 1.57 |
| 2020-03-31 | $15.50B | $10.81B | 1.43 |
| 2019-12-31 | $15.67B | $10.86B | 1.44 |
| 2019-09-30 | $16.12B | $10.49B | 1.54 |
| 2019-06-30 | $15.20B | $9.06B | 1.68 |
| 2019-03-31 | $14.41B | $9.11B | 1.58 |
| 2018-12-31 | $14.63B | $9.01B | 1.62 |
| 2018-09-30 | $18.20B | $12.78B | 1.42 |
| 2018-06-30 | $14.12B | $8.95B | 1.58 |
| 2018-03-31 | $14.96B | $9.01B | 1.66 |
| 2017-12-31 | $20.15B | $8.91B | 2.26 |
| 2017-09-30 | $21.38B | $7.94B | 2.69 |
| 2017-06-30 | $19.98B | $6.80B | 2.94 |
| 2017-03-31 | $19.33B | $6.65B | 2.91 |
| 2016-12-31 | $26.78B | $6.66B | 4.02 |
| 2016-09-30 | $12.98B | $8.32B | 1.56 |
| 2016-06-30 | $12.99B | $8.67B | 1.50 |
| 2016-03-31 | $12.41B | $8.39B | 1.48 |
| 2015-12-31 | $14.16B | $9.19B | 1.54 |
| 2015-09-30 | $15.89B | $8.76B | 1.82 |
| 2015-06-30 | $21.13B | $9.19B | 2.30 |
| 2015-03-31 | $19.99B | $9.21B | 2.17 |
| 2014-12-31 | $13.56B | $10.47B | 1.30 |
| 2014-09-30 | $16.46B | $10.82B | 1.52 |
| 2014-06-30 | $18.26B | $9.85B | 1.85 |
| 2014-03-31 | $17.93B | $10.19B | 1.76 |
| 2013-12-31 | $19.25B | $9.51B | 2.03 |
| 2013-09-30 | $19.75B | $11.33B | 1.74 |
| 2013-06-30 | $19.83B | $10.92B | 1.82 |
| 2013-03-31 | $19.10B | $10.41B | 1.84 |
| 2012-12-31 | $31.32B | $13.28B | 2.36 |
| 2012-09-30 | $27.26B | $16.29B | 1.67 |
| 2012-06-30 | $26.26B | $17.12B | 1.53 |
| 2012-03-31 | $25.60B | $16.79B | 1.53 |
| 2011-12-31 | $23.77B | $15.48B | 1.54 |
| 2011-09-30 | $23.09B | $15.41B | 1.50 |
| 2011-06-30 | $24.13B | $15.84B | 1.52 |
| 2011-03-31 | $23.65B | $17.23B | 1.37 |
| 2010-12-31 | $22.32B | $17.26B | 1.29 |
| 2010-09-30 | $19.45B | $15.58B | 1.25 |
| 2010-06-30 | $19.92B | $14.69B | 1.36 |
| 2010-03-31 | $17.69B | $15.18B | 1.17 |
| 2009-12-31 | $23.31B | $13.05B | 1.79 |
| 2009-09-30 | $21.42B | $12.53B | 1.71 |
| 2009-06-30 | $19.63B | $12.04B | 1.63 |
| 2009-03-31 | $18.01B | $11.77B | 1.53 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $196.826B | $40.109B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stryker (SYK) | United States | $146.166B | 32.94 |
| Boston Scientific (BSX) | United States | $145.408B | 41.81 |
| EssilorLuxottica (ESLOY) | France | $115.383B | 0.00 |
| Medtronic (MDT) | Ireland | $112.944B | 16.78 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.849B | 0.00 |
| Haleon (HLN) | United Kingdom | $41.827B | 27.18 |
| GE HealthCare Technologies (GEHC) | United States | $38.715B | 20.08 |
| ResMed (RMD) | United States | $35.199B | 28.92 |
| Terumo (TRUMY) | Japan | $27.980B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $24.250B | 18.56 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.811B | 13.89 |
| Insulet (PODD) | United States | $19.347B | 77.04 |
| Baxter (BAX) | United States | $15.818B | 10.29 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.057B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.586B | 32.58 |
| BellRing Brands (BRBR) | United States | $9.323B | 37.51 |
| Demant (WILYY) | Denmark | $8.735B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.360B | 14.78 |
| ICU Medical (ICUI) | United States | $4.012B | 38.20 |
| Prestige Consumer Healthcare (PBH) | United States | $3.882B | 19.31 |
| Haemonetics (HAE) | United States | $3.691B | 18.01 |
| Envista Holdings (NVST) | United States | $3.413B | 25.42 |
| Perrigo (PRGO) | Ireland | $3.252B | 9.57 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.807B | 18.07 |
| GN Store Nord (GNNDY) | Denmark | $2.585B | 16.58 |
| Neogen (NEOG) | United States | $2.508B | 28.90 |
| LeMaitre Vascular (LMAT) | United States | $2.227B | 54.13 |
| AtriCure (ATRC) | United States | $1.876B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.572B | 27.52 |
| AdaptHealth (AHCO) | United States | $1.416B | 10.11 |
| InMode (INMD) | Israel | $1.410B | 8.48 |
| BioLife Solutions (BLFS) | United States | $1.213B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.205B | 0.00 |
| Owens & Minor (OMI) | United States | $1.124B | 8.78 |
| Curaleaf Holdings (CURLF) | Canada | $0.981B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.843B | 14.87 |
| CeriBell (CBLL) | United States | $0.754B | 0.00 |
| Evolus (EOLS) | United States | $0.666B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.623B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.557B | 24.58 |
| Omeros (OMER) | United States | $0.541B | 0.00 |
| Surmodics (SRDX) | United States | $0.527B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.434B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.434B | 0.00 |
| ZimVie (ZIMV) | United States | $0.394B | 33.23 |
| Valneva SE (VALN) | France | $0.355B | 0.00 |
| Quanterix (QTRX) | United States | $0.342B | 0.00 |
| Cerus (CERS) | United States | $0.332B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.317B | 30.18 |
| Biote (BTMD) | United States | $0.306B | 6.71 |
| Sanara MedTech (SMTI) | United States | $0.285B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.272B | 18.25 |
| High Tide (HITI) | Canada | $0.250B | 103.00 |
| Zynex (ZYXI) | United States | $0.245B | 51.20 |
| Canopy Growth (CGC) | Canada | $0.237B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.226B | 3.18 |
| Aurora Cannabis (ACB) | Canada | $0.211B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.211B | 14.56 |
| Organigram Holdings (OGI) | Canada | $0.196B | 0.00 |
| Brainsway (BWAY) | Israel | $0.192B | 102.30 |
| MacroGenics (MGNX) | United States | $0.188B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.168B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.150B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.149B | 18.77 |
| Veru (VERU) | United States | $0.143B | 0.00 |
| Jin Medical (ZJYL) | China | $0.143B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.130B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.87 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.092B | 0.00 |
| INLIF (INLF) | $0.078B | 0.00 | |
| InterCure (INCR) | Israel | $0.077B | 0.00 |
| Exagen (XGN) | United States | $0.070B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.069B | 35.33 |
| Jushi Holdings (JUSHF) | United States | $0.063B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.058B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.056B | 0.00 |
| Apyx Medical (APYX) | United States | $0.052B | 0.00 |
| ImmuCell (ICCC) | United States | $0.049B | 0.00 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.017B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 14.11 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |